SALT LAKE CITY, UTAH--A new study from Fox Chase Cancer Center, Philadelphia, Pa., demonstrates that the current guidelines for assessing treatment outcome following radiation therapy overestimates progression when hormone therapy is added. The study results were presented today by Mark Buyyounouski, M.D., a resident in Fox Chase Cancer Center's department of radiation oncology, at the 45th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Salt Lake City, Utah.
Hormone therapy, or androgen deprivation, is commonly combined with radiation therapy to treat prostate cancer patients who have an intermediate or high risk of recurrence. Biochemical failure, or disease progression evidenced only by an elevated or rising PSA, is a useful early measure of prostate cancer treatment outcome for physicians. The ASTRO consensus definition of biochemical failure was tested in this study to determine its usefulness following the combined treatment regimen.
"Biochemical failure is declared, meaning there is high probability of future rises in PSA, if a patient has three consecutive rises in post-treatment PSA levels following treatment," explained Buyyounouski. "Upon the completion of hormone therapy, PSA levels rise modestly. However, not all patients will experience continued rises in the years following treatment. Approximately 20 to 30 percent will have three consecutive rises constituting biochemical failure but will not experience continued rises in later years following radiation therapy with androgen deprivation.
"Additional study is required to determine the ideal definition of biochemical failure that most accurately predicts for future progression of disease. Hopefully, improvements in the definition of biochemical failure will further aid physicians is counseling patients about selecting the most appropriate treatment."
Other study authors include Alexandra L. Hanlon, Ph.D., and Alan Pollack, M.D., PhPage: 1 2 Related medicine news :1
Contact: Karen Carter Mallet
Fox Chase Cancer Center
. ESC releases the first European Guidelines on Percutaneous Coronary Interventions (PCI)2
. Guidelines restricting endoscopy referrals put patients at risk3
. Guidelines for following pediatric cancer survivors aim to reduce medical complications4
. Guidelines issued for metabolic complications related to HIV & antiretrovirals5
. Guidelines do not prevent deliberate self harm6
. Guidelines lacking for patients hospitalized for heart failure7
. Guidelines needed to prevent spread of infection in European hospitals8
. Guidelines recommend EEG to evaluate childrens first nonfebrile seizure9
. Mayo Clinic Cardiologist Available To Discuss New Guidelines On Treatment Of Stable Angina10
. American Psychiatric Association Plans First Comprehensive Guidelines For HIV/AIDS Treatment11
. Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web